查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2151965

醫藥5.0市場規模、佔有率和趨勢分析報告：按類型、技術、應用、最終用途、地區和細分市場預測（2026-2033年）

Pharma 5.0 Market Size, Share & Trends Analysis Report By Type, By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

「醫藥5.0」市場概述

全球醫藥 5.0 市場預計到 2025 年將達到 79 億美元，從 2026 年的 94 億美元成長到 2033 年的 376 億美元，2026 年至 2033 年的複合年成長率為 21.9%。

北美市場處於領先地位，到 2025 年將佔全球銷售額的 43.1%。市場成長的驅動力是人工智慧、數位孿生、先進機器人、基因組學、智慧供應鏈解決方案和永續製造技術的日益普及，這些技術旨在增強藥物創新、營運效率和以患者為中心的護理。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 產業分析工具

第4章：按類型進行業務分析

  • 醫藥5.0市場：按類型分類的趨勢分析
  • 軟體
  • 服務

第5章：依技術進行業務分析

  • 醫藥5.0市場：依技術分類的趨勢分析
  • 人工智慧（AI）和生成式人工智慧
  • 數位孿生與製程模擬技術
  • 基因組學和多體學技術
  • 先進機器人技術
  • 智慧供應鏈技術
  • 永續製造技術
  • 其他（AR、VR、MR、互聯勞動力技術）

第6章 應用業務分析

  • 醫藥5.0市場：按應用領域分類的趨勢分析
  • 藥物發現與開發
  • 智慧製造和製程最佳化
  • 個性化藥物的研發與生產
  • 供應鏈管理與物流
  • 品管和法規遵從
  • 永續性和資源最佳化

第7章 依最終用途進行業務分析

  • 醫藥5.0市場：依最終用途分類的趨勢分析
  • 製藥公司
  • 生技公司
  • CDMO
  • CRO
  • 學術研究機構

第8章 區域業務分析

  • 醫藥5.0市佔率：依地區分類，2025年及2033年
  • 北美洲
    • 北美醫藥5.0市場，2021-2033年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲醫藥5.0市場，2021-2033年
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區醫藥5.0市場，2021-2033年
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 拉丁美洲醫藥5.0市場，2021-2033年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • MEA 製藥 5.0 市場，2021-2033
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 公司分類
  • 企業市場占有率及定位分析，2025年
  • 策略規劃
  • 公司簡介列表
    • NVIDIA Corporation
    • Microsoft
    • Siemens
    • Dassault Systemes
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • ABB
    • SAP SE
    • Blue Yonder Group, Inc.（Acquired By Panasonic Holdings Corporation）
    • IBM
    • IQVIA Inc.
    • Merck KGaA
    • Relay Therapeutics
    • Certara
    • XtalPi
Product Code: GVR-4-68041-027-7

Pharma 5.0 Market Summary

The global pharma 5.0 market size was valued at USD 7.9 billion in 2025 and is projected to grow from USD 9.4 billion in 2026 to USD 37.6 billion by 2033, at a CAGR of 21.9% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 43.1% in 2025. The market growth is driven by the increasing adoption of AI, digital twins, advanced robotics, genomics, intelligent supply chain solutions, and sustainable manufacturing technologies to enhance pharmaceutical innovation, operational efficiency, and patient-centric care.

Global Pharma 5.0 Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Pharma 5.0 market report based on type, technology, application, end-use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Software
  • Services
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Artificial Intelligence (AI) & Generative AI
  • Digital Twin & Process Simulation Technologies
  • Genomics & Multi-omics Technologies
  • Advanced Robotics
  • Intelligent Supply Chain Technologies
  • Sustainable Manufacturing Technologies
  • Others (AR, VR, MR, Connected Workforce Technologies)
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Drug Discovery & Development
  • Smart Manufacturing & Process Optimization
  • Personalized Medicine Development & Manufacturing
  • Supply Chain Management & Logistics
  • Quality Management & Regulatory Compliance
  • Sustainability & Resource Optimization
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical Companies
  • Biotechnology Companies
  • CDMOs
  • CROs
  • Academic & Research Institutes
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. Application Segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. List of Secondary Sources
    • 1.9.3. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Expansion of Digital Twins and Simulation Technologies
      • 3.2.1.2. Growing Adoption of AI and Generative AI
      • 3.2.1.3. Advancements in Genomics and Multi-Omics Technologies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Data Privacy and Cybersecurity Concerns
      • 3.2.2.2. Complex Regulatory Requirements For AI-Driven Technologies
    • 3.2.3. Market Opportunities Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Economic landscape
      • 3.3.2.5. Legal landscape

Chapter 4. Type Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pharma 5.0 Market: Type Movement Analysis
  • 4.3. Software
    • 4.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 4.4. Services
    • 4.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pharma 5.0 Market: Technology Movement Analysis
  • 5.3. Artificial Intelligence (AI) & Generative AI
    • 5.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.4. Digital Twin & Process Simulation Technologies
    • 5.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.5. Genomics & Multi-omics Technologies
    • 5.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.6. Advanced Robotics
    • 5.6.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.7. Intelligent Supply Chain Technologies
    • 5.7.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.8. Sustainable Manufacturing Technologies
    • 5.8.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 5.9. Others (AR, VR, MR, Connected Workforce Technologies)
    • 5.9.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pharma 5.0 Market: Application Movement Analysis
  • 6.3. Drug Discovery & Development
    • 6.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.4. Smart Manufacturing & Process Optimization
    • 6.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.5. Personalized Medicine Development & Manufacturing
    • 6.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.6. Supply Chain Management & Logistics
    • 6.6.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.7. Quality Management & Regulatory Compliance
    • 6.7.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 6.8. Sustainability & Resource Optimization
    • 6.8.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. Pharma 5.0 Market: End Use Movement Analysis
  • 7.3. Pharmaceutical Companies
    • 7.3.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.4. Biotechnology Companies
    • 7.4.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.5. CDMOs
    • 7.5.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.6. CROs
    • 7.6.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.7. Academic & Research Institutes
    • 7.7.1. Market Estimates and Forecast, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Pharma 5.0 Market Share By Region, 2025 & 2033
  • 8.2. North America
    • 8.2.1. North America Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Competitive Scenario
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. U.S. Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Canada Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Competitive Scenario
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Mexico Pharma 5.0 Market, 2021 - 2033 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. UK Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Germany Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. France Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Italy Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Spain Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Denmark Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Sweden Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Norway Pharma 5.0 Market, 2021 - 2033 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Japan Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. China Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. India Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Australia Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Thailand Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. South Korea Pharma 5.0 Market, 2021 - 2033 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Brazil Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Argentina Pharma 5.0 Market, 2021 - 2033 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. South Africa Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Saudi Arabia Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. UAE Pharma 5.0 Market, 2021 - 2033 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Kuwait Pharma 5.0 Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Share/ Position Analysis, 2025
  • 9.3. Strategy Mapping
  • 9.4. Company Profiles/Listing
    • 9.4.1. NVIDIA Corporation
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product/Service Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Microsoft
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product/Service Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Siemens
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product/Service Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Dassault Systemes
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product/Service Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Illumina, Inc.
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product/Service Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Thermo Fisher Scientific Inc.
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product/Service Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. ABB
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product/Service Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. SAP SE
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product/Service Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Blue Yonder Group, Inc. (Acquired By Panasonic Holdings Corporation)
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product/Service Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. IBM
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product/Service Benchmarking
      • 9.4.10.4. Strategic Initiatives
    • 9.4.11. IQVIA Inc.
      • 9.4.11.1. Overview
      • 9.4.11.2. Financial Performance
      • 9.4.11.3. Product/Service Benchmarking
      • 9.4.11.4. Strategic Initiatives
    • 9.4.12. Merck KGaA
      • 9.4.12.1. Overview
      • 9.4.12.2. Financial Performance
      • 9.4.12.3. Product/Service Benchmarking
      • 9.4.12.4. Strategic Initiatives
    • 9.4.13. Relay Therapeutics
      • 9.4.13.1. Overview
      • 9.4.13.2. Financial Performance
      • 9.4.13.3. Product/Service Benchmarking
      • 9.4.13.4. Strategic Initiatives
    • 9.4.14. Certara
      • 9.4.14.1. Overview
      • 9.4.14.2. Financial Performance
      • 9.4.14.3. Product/Service Benchmarking
      • 9.4.14.4. Strategic Initiatives
    • 9.4.15. XtalPi
      • 9.4.15.1. Overview
      • 9.4.15.2. Financial Performance
      • 9.4.15.3. Product/Service Benchmarking
      • 9.4.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 4 Global pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 5 Global pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 6 Global pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 7 Global pharma 5.0 market, by region, 2021 - 2033 (USD Million)
  • Table 8 North America pharma 5.0 market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 10 North America pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 11 North America pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 12 North America pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 13 U.S. pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 14 U.S. pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 15 U.S. pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 16 U.S. pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 17 Canada pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 18 Canada pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 19 Canada pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 20 Canada pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 21 Mexico pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 22 Mexico pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 23 Mexico pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 24 Mexico pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 25 Europe pharma 5.0 market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 27 Europe pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 28 Europe pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 29 Europe pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 30 UK pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 31 UK pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 32 UK pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 33 UK pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Germany pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 35 Germany pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 36 Germany pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 37 Germany pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 38 France pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 39 France pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 40 France pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 41 France pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 42 Italy pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 43 Italy pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 44 Italy pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 45 Italy pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 46 Spain pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 47 Spain pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 48 Spain pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 49 Spain pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 50 Denmark pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 51 Denmark pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 52 Denmark pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 53 Denmark pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 54 Sweden pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 55 Sweden pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 56 Sweden pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 57 Sweden pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 58 Norway pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 59 Norway pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 60 Norway pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 61 Norway pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific pharma 5.0 market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 67 Japan pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 68 Japan pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 69 Japan pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 70 Japan pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 71 China pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 72 China pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 73 China pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 74 China pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 75 India pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 76 India pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 77 India pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 78 India pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 79 Australia pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 80 Australia pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 81 Australia pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 82 Australia pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 83 Thailand pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 84 Thailand pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 85 Thailand pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 86 Thailand pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 87 South Korea pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 88 South Korea pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 89 South Korea pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 90 South Korea pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 91 Latin America pharma 5.0 market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 93 Latin America pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 94 Latin America pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 95 Latin America pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 96 Brazil pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 97 Brazil pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 98 Brazil pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 99 Brazil pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 100 Argentina pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 101 Argentina pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 102 Argentina pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 103 Argentina pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa pharma 5.0 market, by country, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 108 Middle East & Africa pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 109 South Africa pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 110 South Africa pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 111 South Africa pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 112 South Africa pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 117 UAE pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 118 UAE pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 119 UAE pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 120 UAE pharma 5.0 market, by end use, 2021 - 2033 (USD Million)
  • Table 121 Kuwait pharma 5.0 market, by type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait pharma 5.0 market, by technology, 2021 - 2033 (USD Million)
  • Table 123 Kuwait pharma 5.0 market, by application, 2021 - 2033 (USD Million)
  • Table 124 Kuwait pharma 5.0 market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Pharma 5.0 market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market outlook
  • Fig. 8 Segment snapshot
  • Fig. 9 Competitive landscape snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Pharma 5.0 market driver analysis
  • Fig. 12 Pharma 5.0 market restraint analysis
  • Fig. 13 Pharma 5.0 market: Porter's five forces analysis
  • Fig. 14 Pharma 5.0 market: PESTLE analysis
  • Fig. 15 Pharma 5.0 market: Type outlook and key takeaways
  • Fig. 16 pharma 5.0 market: Type market share analysis
  • Fig. 17 Software market, 2021 - 2033 (USD Million)
  • Fig. 18 Services market, 2021 - 2033 (USD Million)
  • Fig. 19 Pharma 5.0 market: Technology outlook and key takeaways
  • Fig. 20 pharma 5.0 market: Technology market share analysis
  • Fig. 21 Artificial intelligence (AI) & generative AI market, 2021 - 2033 (USD Million)
  • Fig. 22 Digital twin & process simulation technologies market, 2021 - 2033 (USD Million)
  • Fig. 23 Genomics & multi-omics technologies market, 2021 - 2033 (USD Million)
  • Fig. 24 Advanced robotics market, 2021 - 2033 (USD Million)
  • Fig. 25 Intelligent supply chain technologies market, 2021 - 2033 (USD Million)
  • Fig. 26 Sustainable manufacturing technologies market, 2021 - 2033 (USD Million)
  • Fig. 27 Others (AR, VR, MR, connected workforce technologies) market, 2021 - 2033 (USD Million)
  • Fig. 28 Pharma 5.0 market: Application outlook and key takeaways
  • Fig. 29 Pharma 5.0 market: Application market share analysis
  • Fig. 30 Drug discovery & development market, 2021 - 2033 (USD Million)
  • Fig. 31 Smart manufacturing & process optimization market, 2021 - 2033 (USD Million)
  • Fig. 32 Personalized medicine development & manufacturing market, 2021 - 2033 (USD Million)
  • Fig. 33 Supply chain management & logistics market, 2021 - 2033 (USD Million)
  • Fig. 34 Quality management & regulatory compliance market, 2021 - 2033 (USD Million)
  • Fig. 35 Sustainability & resource optimization market, 2021 - 2033 (USD Million)
  • Fig. 36 Pharma 5.0 market: End use outlook and key takeaways
  • Fig. 37 Pharma 5.0 market: End use market share analysis
  • Fig. 38 Pharmaceutical companies market, 2021 - 2033 (USD Million)
  • Fig. 39 Biotechnology companies market, 2021 - 2033 (USD Million)
  • Fig. 40 CDMOs market, 2021 - 2033 (USD Million)
  • Fig. 41 CROs market, 2021 - 2033 (USD Million)
  • Fig. 42 Academic & research institutes market, 2021 - 2033 (USD Million)
  • Fig. 43 Regional marketplace: Key takeaways
  • Fig. 44 North America pharma 5.0 market, by country, 2021 -2033 (USD Million)
  • Fig. 45 U.S. pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 46 Canada pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 47 Mexico pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 48 Europe pharma 5.0 market, by country, 2021 -2033 (USD Million)
  • Fig. 49 UK pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 50 Germany pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 51 France pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 52 Italy pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 53 Spain pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 55 Sweden pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 56 Norway pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 57 Asia-Pacific pharma 5.0 market, by country, 2021 -2033 (USD Million)
  • Fig. 58 Japan pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 59 China pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 60 India pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 61 Australia pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 62 Thailand pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 63 South Korea pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 64 Latin America pharma 5.0 market, by country, 2021 -2033 (USD Million)
  • Fig. 65 Brazil pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 66 Argentina pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 67 MEA pharma 5.0 market, by country, 2021 -2033 (USD Million)
  • Fig. 68 South Africa pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 69 Saudi Arabia pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 70 UAE pharma 5.0 market, 2021 - 2033 (USD Million)
  • Fig. 71 Kuwait pharma 5.0 market, 2021 - 2033 (USD Million)